To make sure that Hadassah is equipped and able to continue treating COVID-19 patients for many months to come, Hadassah International’s Global Response Team has launched a COVID-19 Crowd Funding Campaign that is being highly endorsed by celebrities across Israel and throughout the world.

The Hadassah Hospital in Ein Kerem has been at the forefront of patient care, research and innovative drug trials to find an effective treatment for COVID-19 since the outbreak in Israel.

The Hospital has treated, over the past month, more than 900 COVID-19 patients. 40 patients required ICU care and 24 were ventilated.

Thanks to careful social distancing and isolation, the overall number of COVID-19 patients in Jerusalem continues to decrease gradually. However, we still have many patients in our COVID-19 Hospital in the Round Building at Hadassah Ein Kerem. It is becoming clear that we must maintain the highest quality of medicine to support and cope with both current and new patients over time.

Returning to some degree of normalcy will not be easy. Our doctors, nurses, and staff will continue to be on the front-lines of treatment of coronavirus patients for the benefit of all the residents of Jerusalem and its surrounding areas for some time to come.

Moreover, it is our priority to prepare for the expected second wave of COVID-19 patients. To make sure that we have the necessary equipment with sufficient patient beds for ventilated ICU patients.

Based on our experience in Jerusalem – which includes several densely populated neighborhoods – we have reason to believe that during this second wave, we will once again need to treat COVID-19 patients in serious condition at a higher rate than other areas in Israel.

After watching the video below that explains why your contribution will make such a difference, please click here to Donate and participate in this very important campaign.

 

Please view this video:

 

Read more about the COVID-19 Global Crisis Response Team.

Read more about groundbreaking COVID-19 Research at Hadassah.